Immuneering Corp
IMRX
查看详细走势图
4.930USD
+0.410+9.07%
收盘 02/06, 16:00（美东）报价延迟15分钟
312.97M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+9.07%
5天
+6.48%
1月
-40.82%
6月
+40.46%
今年开始到现在
-25.08%
1年
+159.47%
查看详细走势图
TradingKey Immuneering Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
Immuneering Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名118/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.83。中期看，股价处于下降通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Immuneering Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Immuneering Corp亮点
亮点风险
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-2.76，处于3年历史合理位
机构加仓
最新机构持股31.36M股，环比增加40.99%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值3.60K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.58
分析师目标
根据
6
位分析师
买入
评级
16.833
目标均价
+255.13%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Immuneering Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Immuneering Corp简介
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
公司代码IMRX
公司Immuneering Corp
CEOZeskind (Benjamin J)
网址https://immuneering.com/
相关品种
